Literature DB >> 11118059

The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells.

Z Song1, W C Powell, N Kasahara, A van Bokhoven, G J Miller, P Roy-Burman.   

Abstract

Fibroblast growth factor 8, isoform b (FGF8b), has been implicated in the oncogenesis of the prostate and mammary epithelia. We examined whether overexpression of FGF8b in a weakly tumorigenic prostate carcinoma cell line, LNCaP, could alter the growth and tumorigenic properties of these cells. LNCaP cells were infected with a lentivirus vector carrying FGF8b cDNA and the green fluorescent protein (GFP) cDNA in the same construct, and the infected cell population was sorted on the basis of GFP protein expression. It was demonstrated that, in comparison with the cells transduced with GFP-vector alone, LNCaP cells with FGF8b-GFP expression manifested an increased growth rate, higher soft agar clonogenic efficiency, enhanced in vitro invasion, and increased in vivo tumorigenesis. Most strikingly, whereas parental or vector-control LNCaP cells failed to grow at all in an in vivo tumorigenesis/diaphragm invasion assay in nude mice, the cells overexpressing FGF8b proliferated as deposits of tumor cells on the diaphragm, frequently with indications of tumor cell invasion into the diaphragm. Coculturing of primary prostatic or non-prostatic stromal cells with the infected LNCaP cells led us to observe that: (a) stromal cells, irrespective of tissue origin, strongly suppressed LNCaP cell growth; (b) FGF8b producing LNCaP cells could partially evade the stromal inhibition, perhaps from the autocrine stimulatory effect of FGF8b; and (c) production of FGF8b in the coculture had a stimulatory effect on the proliferation of the stromal cells, prostatic or non-prostatic. This stimulation was not attributable to the direct action of FGF8b on stromal cells. Instead, it appears that epithelial-stromal cell-cell contact and some unknown soluble factors secreted by LNCaP cells upon stimulation of FGF8b are required for the maximal effect. Together, these results suggest that the growth rate and biological behavior of prostatic cancer cells can be altered to a more aggressive phenotype by up-regulation of FGF8b expression. These changes in phenotype also influence the interaction of the affected cells with stromal cells. The data obtained may have direct relevance to the progression of prostate cancer, recognizing that FGF8b is naturally overexpressed in advanced disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118059

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor.

Authors:  Yi Lu; Jian Zhang; Jinlu Dai; Lindsay A Dehne; Atsushi Mizokami; Zhi Yao; Evan T Keller
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

2.  Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients.

Authors:  J Liu; P You; G Chen; X Fu; X Zeng; C Wang; Y Huang; L An; X Wan; N Navone; C-L Wu; W L McKeehan; Z Zhang; W Zhong; F Wang
Journal:  Oncogene       Date:  2015-06-22       Impact factor: 9.867

3.  Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.

Authors:  Carlo Vicentini; Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; Angelo Marronaro; Mauro Bologna
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-04       Impact factor: 4.553

4.  Assay-based response evaluation in head and neck oncology: requirements for better decision making.

Authors:  Andreas Dietz; Andreas Boehm; Iris-Susanne Horn; Pierre Kruber; Ingo Bechmann; Wojciech Golusinski; Dietger Niederwieser; Ralph Dollner; Torsten W Remmerbach; Christian Wittekind; Stephan Dietzsch; Guido Hildebrandt; Gunnar Wichmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-06       Impact factor: 2.503

5.  Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts.

Authors:  Johanna Tuomela; Tove J Grönroos; Maija P Valta; Jouko Sandholm; Aleksi Schrey; Jani Seppänen; Päivi Marjamäki; Sarita Forsback; Ilpo Kinnunen; Olof Solin; Heikki Minn; Pirkko L Härkönen
Journal:  BMC Cancer       Date:  2010-10-30       Impact factor: 4.430

6.  Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.

Authors:  A F West; M O'Donnell; R G Charlton; D E Neal; H Y Leung
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

7.  FGF8 promotes colorectal cancer growth and metastasis by activating YAP1.

Authors:  Rui Liu; Shan Huang; Yunlong Lei; Tao Zhang; Kui Wang; Bo Liu; Edouard C Nice; Rong Xiang; Ke Xie; Jingyi Li; Canhua Huang
Journal:  Oncotarget       Date:  2015-01-20

8.  Overexpression of FGF9 in prostate epithelial cells augments reactive stroma formation and promotes prostate cancer progression.

Authors:  Yanqing Huang; Chengliu Jin; Tomoaki Hamana; Junchen Liu; Cong Wang; Lei An; Wallace L McKeehan; Fen Wang
Journal:  Int J Biol Sci       Date:  2015-06-11       Impact factor: 6.580

9.  FGF8 isoform b expression in human prostate cancer.

Authors:  V J Gnanapragasam; M C Robinson; C Marsh; C N Robson; F C Hamdy; H Y Leung
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

10.  A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers.

Authors:  Arianna Giacomini; Sara Matarazzo; Katiuscia Pagano; Laura Ragona; Sara Rezzola; Michela Corsini; Emanuela Di Salle; Marco Presta; Roberto Ronca
Journal:  Oncotarget       Date:  2015-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.